This month’s new hires and promotions include executive appointments at Advarra, Eversana, Signant Health, Endpoint Clinical and other companies.
This month’s new hires and promotions include executive appointments at Advarra, Eversana, Signant Health, Endpoint Clinical and other companies.
Advarra—an institutional review board (IRB), institutional biosafety committee (IBC), research quality and compliance consulting services, and standards-based research technology solutions provider—has appointed Gadi Saarony as CRO.
Saarony said regarding his hire, “The team’s commitment to the advancement of clinical research, and to the well-being of clinical trial participants is truly inspiring. Advarra’s capabilities and track record, combined with the healthcare expertise and experience available to it from Genstar, puts us in a great position to innovate, accelerate cycle-times, and drive safety and compliance in support of drug development.”
Kelly Baker has been named CFO of Eversana, a global company providing commercial services to the life-sciences industry. In her new role, she will direct the firm’s financial activity, and lead the platform's investment and growth strategies.
Baker said of her new firm, “Backed by owners who share our vision and values, we are investing in the commercial services and technology solutions that meet our clients’ ever evolving needs. It’s exciting to have a front seat in creating a healthier world for all.”
Baker brings more than 15 years of leadership experience in the healthcare sector, most recently leading finance with the DuPage Medical group. In her previous finance executive leadership role at OptumRx, she led several key acquisition programs; other experience includes equities trading and financial analyst roles at Goldman Sachs.
Portuguese CDMO Hovione has named Jean-Luc Herbeaux CEO of the company. He will work directly with other leadership to create and execute the firm’s corporate strategy and vision.
Herbeaux commented, “Hovione is a company with a great vision, great people and great science and it has an important role in the pharma industry. I look forward to working with…the Hovione Team to bring this already successful company to new heights."
Herbeaux brings to the company 20 years of experience at Evonik, where he helped drive the company’s growth agenda. Prior to joining that company, he held senior positions at firms in Europe and Asia.
Artificial intelligence (AI) and data analytics company AiCure has named Ed Ikeguchi as its CEO. Previously CMO and president, he will be responsible for advancing the company’s solutions for improving health through applied scientific technology in clinical trials.
Ikeguchi said, “It is my privilege to lead the company in its next chapter as we work toward holistic health delivery, deepen our understanding of patients’ lived experience, and elevate the credibility of clinical trial results. We are poised to build on our strong momentum and further make our mark in patient care and drug development.”
Before joining AiCure as CMO in 2018, Ikeguchi co-founded Medidata Solutions in 2009. He offers a range of experience in both clinical environments and the C-suite.
Patient-centric trial technology provider Signant Health has named Ian Jennings chief commercial officer. He will help shape strategy and direction for the company’s commercial teams.
Mike Nolte, CEO of Signant Health, said, "Ian has a very strong background in clinical and healthcare technology with experience in eCOA, IRT, patient engagement and real-world evidence, and is a strong believer in the power of high performing teams. We believe that Ian is the perfect addition to our leadership team to guide our commercial future in 2020 and beyond.”
Jennings has approximately 30 years of commercial technology experience in the life sciences industry. He has held positions at a number of companies, including ClinPhone, Parexel Informatics, Exco InTouch and ERT.
Endpoint Clinical, an interactive response technology (IRT) firm serving the life-science industry, has appointed Christine Oliver as CEO. Her responsibilities will include continuing to drive the company’s position in the marketplace.
Oliver brings more than 20 years of experience combining a passion for advancing clinical technology with an entrepreneurial mindset to drive change in getting therapies to patients faster. Before joining Endpoint in 2013, she served in a number of pharma/biotech industry roles, including a five-year tenure with Takeda Oncology.
Arvita Triparti has been named senior director of QTC for Endpoint Clinical, a life-sciences interactive response technology (IRT) solutions firm. She will help the company ensure data privacy, and regulatory and data security, for its clients.
Triparti brings to the company more than a decade of leadership in quality management, including work in various life-science environments. Her accomplishments include help to secure various high-profile product approvals, including the first EU authorization for an Apple Watch EKG accessory.
Interactive response technology (IRT) solutions provider Endpoint Clinical has named Cat Hall vice president of product strategy. She will use her expertise in pharma supply chain management to help shape the company’s IRT technology and services.
Hall began her career as an academic scientist in molecular and cellular areas before transitioning into pharma supply chain management. She first joined Endpoint in 2019 as vice president of product strategy, to ensure the customer voice helped shape the company’s solutions.
UPS, a global logistics provider whose Marken division serves the clinical trial field, has named Carol Tomé CEO; she will assume the role June 1. She had joined the company’s board of directors in 2003.
Prior to coming on board at UPS, she had been vice president at Home Depot, after spending about 25 years with the company. Before that, she worked in the banking and finance industry.
Tomé serves as a trustee or board member for a number of organizations including Grady Hospital. She also serves as Chair of the Policy Advisory Board for the Harvard Joint Center for Housing Studies and Vice Chair of the Board of Trustees for the Atlanta Botanical Garden.
